Research ExplorerPublicationsDo we need 5-FU in addition to cisplatin for chemoradiation ...

Do we need 5-FU in addition to cisplatin for chemoradiation of locally advanced head-and-neck cancer?

Standard

Do we need 5-FU in addition to cisplatin for chemoradiation of locally advanced head-and-neck cancer? / Rades, Dirk; Seidl, Daniel; Janssen, Stefan; Bajrovic, Amira; Hakim, Samer G; Wollenberg, Barbara; Schild, Steven E.

In: ORAL ONCOL, Vol. 57, 06.2016, p. 40-5.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Rades, D, Seidl, D, Janssen, S, Bajrovic, A, Hakim, SG, Wollenberg, B & Schild, SE 2016, 'Do we need 5-FU in addition to cisplatin for chemoradiation of locally advanced head-and-neck cancer?', ORAL ONCOL, vol. 57, pp. 40-5. https://doi.org/10.1016/j.oraloncology.2016.04.003

APA

Rades, D., Seidl, D., Janssen, S., Bajrovic, A., Hakim, S. G., Wollenberg, B., & Schild, S. E. (2016). Do we need 5-FU in addition to cisplatin for chemoradiation of locally advanced head-and-neck cancer? ORAL ONCOL, 57, 40-5. https://doi.org/10.1016/j.oraloncology.2016.04.003

Vancouver

Rades D, Seidl D, Janssen S, Bajrovic A, Hakim SG, Wollenberg B et al. Do we need 5-FU in addition to cisplatin for chemoradiation of locally advanced head-and-neck cancer? ORAL ONCOL. 2016 Jun;57:40-5. https://doi.org/10.1016/j.oraloncology.2016.04.003

Bibtex

@article{65acf96b716548c6a0e01286a6ebd1d0,
title = "Do we need 5-FU in addition to cisplatin for chemoradiation of locally advanced head-and-neck cancer?",
abstract = "OBJECTIVES: To compare chemoradiation with cisplatin alone or cisplatin plus 5-FU for locally advanced squamous cell carcinoma of the head-and-neck (SCCHN).MATERIALS AND METHODS: The outcomes of 142 patients who received chemoradiation with cisplatin alone for locally advanced SCCHN were retrospectively compared to 170 patients who received cisplatin plus 5-fluorouracil (5-FU). The outcomes compared included loco-regional control (LRC), metastases-free survival (MFS), overall survival (OS) and adverse events.RESULTS: Although patients who received cisplatin alone had a significantly worse performance status, 81% of these patients completed planned chemotherapy compared to 73% of patients in the cisplatin plus 5-FU group (p=0.18). Radiotherapy breaks >1week were necessary in 14% and 23% of patients, respectively (p=0.09). The 5-year LRC rates were 69% after cisplatin alone and 68% after cisplatin plus 5-FU (p=0.71). The 5-year MFS rates were 72% and 62%, respectively (p=0.37), and 5-year OS rates were 60% and 45%, respectively (p=0.066). On multivariate analysis, cisplatin alone was significantly associated with improved OS (RR 1.35; 95%-CI 1.09-1.69; p=0.006). Nausea/vomiting, pneumonia/sepsis and late adverse events occurred more common in the cisplatin plus 5-FU group.CONCLUSION: Given the limitations of a retrospective study, chemoradiation with cisplatin alone appeared associated with fewer adverse events and better OS than with cisplatin plus 5-FU in patients with locally advanced SCCHN. Thus, 5-FU in addition to cisplatin may be omitted for these patients. A randomized trial is warranted to confirm these findings.",
keywords = "Journal Article",
author = "Dirk Rades and Daniel Seidl and Stefan Janssen and Amira Bajrovic and Hakim, {Samer G} and Barbara Wollenberg and Schild, {Steven E}",
note = "Copyright {\textcopyright} 2016 Elsevier Ltd. All rights reserved.",
year = "2016",
month = jun,
doi = "10.1016/j.oraloncology.2016.04.003",
language = "English",
volume = "57",
pages = "40--5",
journal = "ORAL ONCOL",
issn = "1368-8375",
publisher = "Elsevier Limited",

}

RIS

TY - JOUR

T1 - Do we need 5-FU in addition to cisplatin for chemoradiation of locally advanced head-and-neck cancer?

AU - Rades, Dirk

AU - Seidl, Daniel

AU - Janssen, Stefan

AU - Bajrovic, Amira

AU - Hakim, Samer G

AU - Wollenberg, Barbara

AU - Schild, Steven E

N1 - Copyright © 2016 Elsevier Ltd. All rights reserved.

PY - 2016/6

Y1 - 2016/6

N2 - OBJECTIVES: To compare chemoradiation with cisplatin alone or cisplatin plus 5-FU for locally advanced squamous cell carcinoma of the head-and-neck (SCCHN).MATERIALS AND METHODS: The outcomes of 142 patients who received chemoradiation with cisplatin alone for locally advanced SCCHN were retrospectively compared to 170 patients who received cisplatin plus 5-fluorouracil (5-FU). The outcomes compared included loco-regional control (LRC), metastases-free survival (MFS), overall survival (OS) and adverse events.RESULTS: Although patients who received cisplatin alone had a significantly worse performance status, 81% of these patients completed planned chemotherapy compared to 73% of patients in the cisplatin plus 5-FU group (p=0.18). Radiotherapy breaks >1week were necessary in 14% and 23% of patients, respectively (p=0.09). The 5-year LRC rates were 69% after cisplatin alone and 68% after cisplatin plus 5-FU (p=0.71). The 5-year MFS rates were 72% and 62%, respectively (p=0.37), and 5-year OS rates were 60% and 45%, respectively (p=0.066). On multivariate analysis, cisplatin alone was significantly associated with improved OS (RR 1.35; 95%-CI 1.09-1.69; p=0.006). Nausea/vomiting, pneumonia/sepsis and late adverse events occurred more common in the cisplatin plus 5-FU group.CONCLUSION: Given the limitations of a retrospective study, chemoradiation with cisplatin alone appeared associated with fewer adverse events and better OS than with cisplatin plus 5-FU in patients with locally advanced SCCHN. Thus, 5-FU in addition to cisplatin may be omitted for these patients. A randomized trial is warranted to confirm these findings.

AB - OBJECTIVES: To compare chemoradiation with cisplatin alone or cisplatin plus 5-FU for locally advanced squamous cell carcinoma of the head-and-neck (SCCHN).MATERIALS AND METHODS: The outcomes of 142 patients who received chemoradiation with cisplatin alone for locally advanced SCCHN were retrospectively compared to 170 patients who received cisplatin plus 5-fluorouracil (5-FU). The outcomes compared included loco-regional control (LRC), metastases-free survival (MFS), overall survival (OS) and adverse events.RESULTS: Although patients who received cisplatin alone had a significantly worse performance status, 81% of these patients completed planned chemotherapy compared to 73% of patients in the cisplatin plus 5-FU group (p=0.18). Radiotherapy breaks >1week were necessary in 14% and 23% of patients, respectively (p=0.09). The 5-year LRC rates were 69% after cisplatin alone and 68% after cisplatin plus 5-FU (p=0.71). The 5-year MFS rates were 72% and 62%, respectively (p=0.37), and 5-year OS rates were 60% and 45%, respectively (p=0.066). On multivariate analysis, cisplatin alone was significantly associated with improved OS (RR 1.35; 95%-CI 1.09-1.69; p=0.006). Nausea/vomiting, pneumonia/sepsis and late adverse events occurred more common in the cisplatin plus 5-FU group.CONCLUSION: Given the limitations of a retrospective study, chemoradiation with cisplatin alone appeared associated with fewer adverse events and better OS than with cisplatin plus 5-FU in patients with locally advanced SCCHN. Thus, 5-FU in addition to cisplatin may be omitted for these patients. A randomized trial is warranted to confirm these findings.

KW - Journal Article

U2 - 10.1016/j.oraloncology.2016.04.003

DO - 10.1016/j.oraloncology.2016.04.003

M3 - SCORING: Journal article

C2 - 27208843

VL - 57

SP - 40

EP - 45

JO - ORAL ONCOL

JF - ORAL ONCOL

SN - 1368-8375

ER -